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International Agency for Research on Cancer (IARC) estimated that bladder cancer is the ninth most common
cancer in the world, with 430,000 new cases and 165,000 deaths in 2012. Bladder cancer represents the fourth
most common cancer in men and ninth most common cancer in women. It is the second most prevalent cancer
in men 60 years of age or older in United States. Looking further down, continuing advancements in cancer
research could potentially offer more choices for clinician and patient with longer survival and better quality of life.
Although, bladder cancer represents an ideal tumor model to test and apply cancer prevention strategies; there are
limited studies about application of metformin in the management of bladder cancer. Here, I will shed light on the
proposed mechanisms of anti-carcinogenic effects of metformin and cohort of these mechanisms with the novel
application of metformin as therapy of bladder cancer.
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International Agency for Research on Cancer (IARC)
announced that bladder cancer is the ninth most common
cancer in the world, with 430,000 new cases and 165,000
deaths in 2012. Incidence of bladder cancer is predomin-
antly high in males with 77% of the cases, sorting it the 7th
highest on incidence and 9th highest on mortality. For fe-
males it is the 19th highest on incidence and 17th highest
on mortality. The incidence of bladder cancer is almost 3
times higher in more developed countries compared to
less developed countries [1]. At initial diagnosis, about
75–80% of cases are Non-Muscle-Invasive Bladder Cancer
(NMIBC), with the remaining Muscle- Invasive Bladder
Cancer (MIBC) [2]. Transurethral Resection of Bladder
Tumor is standard therapy for NMIBC combined with
subsequent intravesical therapy, with a high five year
survival rates. However, the five year progression and re-
currence rates can add up to 1–45 and 31–78% respect-
ively after the first treatment [3]. Thus, finding successful
way of preventing NMIBC progression and recurrence is
required urgently.Correspondence: ph.amrcapa@gmail.com; amrel_arabey@azhar.edu.eg
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(http://creativecommons.org/publicdomain/zeSeveral risk factors, such as smoking, paint and human
papillomavirus infection, have been involved in carcino-
genesis of urinary bladder [4]. A recent meta-analysis of
15 cohort studies concluded that pre obese has a signifi-
cantly increased risk of bladder cancer by 7%, while
obesity increases the risk of bladder cancer by approxi-
mately 10%. Moreover, the dose–response meta-analysis
of this study shows a linear association between Body
Mass Index (BMI) and bladder cancer, and displays each
5 kg/m2 increment of BMI matched to a 4.2% increase
in risk of bladder cancer [5]. Furthermore, serum levels
of insulin and IGF-1 which increased in obesity and/or
metabolic disease patients may be facilitate tumorigen-
esis, proliferation, survival and appear to be a major
mechanism linking obesity to cancer [6].
Diabetes mellitus (DM) was first investigated as a risk
factor for cancer death at the beginning of the 20th
century, when the etiologies of these two major deadly
diseases
Diabetes mellitus (DM) was first investigated as a risk
factor for cancer death at the beginning of the 20th
century, when the etiologies of these two major deadly
diseases were unknown. The fundamental burden of as-
sociation between cancer and diabetes has been a motiv-
ation for researchers to look for prevention strategies
that can simultaneously affect both diseases and reducele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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ation between DM and cancer is significant for disease
prevention and management. Interestingly, several studies
indicate that patients with diabetes have increased risk of
several malignancies, including bladder, colon and rectum
cancers. In 2013, meta-analysis study concluded that indi-
viduals with diabetes may have more than 35% increased
risk of bladder cancer by comparison with non-diabetes
individuals [7].
Metformin, a biguanide, was approved by the United
States Food and Drug Administration in 1995 as an oral
hypoglycemic agent. Given alone or in combination with
a sulfonylurea, metformin improves glycemic control
and lipid concentrations in patients who respond poorly
to dietary control or to a sulfonylurea alone [8]. In 2005,
the first attracted attention of metformin as promising
drug to suppress not only serum glucose levels but also
the incidence of various cancers in an observational
study [8]. Moreover, metformin is commonly used off-
label for metabolic syndrome [9] and treat weight gain
induced by antipsychotic medications [10].
Randomized controlled trials (RCTs) are widely ad-
mitted as the ‘gold standard’ for accumulating robust
evidence for any health concern intervention. Recently,
the European Institute of Oncology (IEO), Milan, Italy,
was conducted a randomized, phase II, double-blind,
placebo-controlled trial in women with stage I-IIa
breast cancer candidates for elective surgery who re-
ceived either metformin or placebo for 4 weeks before
surgery. The authors concluded that a lower Ki-67 LI
in ductal hyperplasia under metformin in women with
abdominal obesity, the hallmark of insulin resistance, in
line with cancer tissue. Thus, metformin selectively
decreased Ki-67 in Human Epidermal Growth factor
Receptor 2 (HER2)-positive cancers and in women with
extra markers of insulin resistance [11]. Interestingly,
recent study confirmed that patients with low Ki-67 ex-
pressions, negative epidermal growth factor receptor stain-
ing and preoperative positive urine cytology appear to be
more sensitive to intravesical instillations for bladder recur-
rence prevention after radical nephroureterectomy [12].
Although, bladder cancer represents an ideal tumor
model to test and apply cancer prevention strategies;
there are limited studies about application of metformin
in the management of bladder cancer. Furthermore, DM
and obesity are considered as risk factors for bladder
cancer. Metformin, a first-line oral anti-diabetic, has
been demonstrated to prevent cancer and reduce cancer
mortality among diabetic patients in observational stud-
ies [13]. Hence, in this review, I will shed light on the
proposed mechanisms of anti-carcinogenic effects of
metformin and correlation of these mechanisms with
bladder cancer according to recent published literature
(Fig. 1).Anti-carcinogenic effects of metformin
Various epidemiologic studies have shown that metfor-
min is associated with reduced risk of cancer in diabetic
patients [8, 14]. In addition, several studies have shown
that the use of metformin significantly reduces the risk
of cancers like breast [15], pancreatic [16] and prostate
[17]. Interestingly, a recent meta-analyses/systematic
reviews have examined the overall incidence of cancer
in patients with diabetes taking metformin versus not
and this study concluded that patients with diabetes
who are treated with metformin have an approximately
one-third reduction in the overall incidence of cancer
[18]. Moreover, metformin has also been associated
with lower overall cancer-related mortality [19]. Fur-
thermore, the potential antitumor effects of metformin
have been evaluated in numerous in vitro and in vitro
studies on several cancer models including breast,
endometrial, ovarian, pancreatic, lung, prostate, head
and neck carcinomas, acute myeloid leukemia, glioma
[20] and Colorectal cancer carcinogenesis (CRC) [21].
Clinically, the first notified trial of metformin for
inhibiting CRC in humans provides preliminary evi-
dence that metformin suppresses colonic epithelial
proliferation and rectal aberrant crypt foci formation
in humans, suggesting that metformin should be re-
evaluated as promising drug for the chemoprevention
of CRC [22].
Metformin can improve treatment outcomes in pre-
clinical models of cancer, particularly in the obese set-
ting and reduces the incidence of cancer in diabetic
patients as well as improves survival in newly diagnosed
cases. In addition, metformin has been shown to target
cancer cells, transcription factors, microRNAs, DNA
damage, cancer stem cells, and metabolism [6]. Recently,
pioneer work by Incio et al., [23]. proved that metformin
in overweight/obese condition, reprograms the fibro-
inflammatory tumor microenvironment and lately re-
duces metastasis in pancreatic cancer models [23].
Metformin and bladder cancer
Study by Tseng, reported that metformin use is associated
with a decreased risk of bladder cancer in Taiwanese pa-
tients with type-2 DM [24]. Moreover, a single-institution
retrospective cohort study (January 1997 - June 2013) to
examine the association between metformin use and on-
cologic outcomes in 421 of diabetic patients undergoing
radical cystectomy for bladder cancer and the authors
concluded that metformin improves recurrence-free
survival and bladder cancer-specific survival in diabetic
patients undergoing radical cystectomy [25]. In addition,
retrospective study conducted on 1117 patients with
NMIBC at four institutions between 1996 and 2007 con-
cluded that Patients with diabetic mellitus and NMIBC
who do not take metformin seem to be at an increased
Metformin
Proposed Pathways in bladder cancer
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Fig. 1 Proposed mechanisms of anti-carcinogenic effects of metformin against bladder cancer: (1) metformin induces growth inhibition, (2) metformin
regulates insulin and glucose levels, (3) metformin induce cell death, (4) metformin potentiates the cytotoxicity of chemotherapeutic drugs, (5)
metformin’s association with oxidative stress, DNA Damage Response (DDR), (6) immune and hypothalamic effects of metformin and (7) autophagy
effects of metformin
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ingly, a recent study demonstrated that metformin inhibits
the proliferation of bladder cancer cells in vitro and
in vivo [27]. Although, there are currently more than 100
ongoing or upcoming clinical studies assessing the role of
metformin in the therapy cancer, only one ongoing clinical
trial assessing the role of metformin (NCT02360618)
(https://clinicaltrials.gov/ct2/show/NCT02360618) in the
prevention of bladder cancer.
Proposed mechanisms of anticarcinogenic effects of
metformin
The potential beneficial effects of metformin against
cancer are believed to be mediated mainly by one or more
mechanisms that I will discuss further: (1) metformininduces growth inhibition, (2) metformin regulates insulin
and glucose levels, (3) metformin induce cell death, (4)
metformin potentiates the cytotoxicity of chemotherapeu-
tic drugs, (5) metformin’s association with oxidative stress,
DNA Damage Response (DDR), (6) immune and hypo-
thalamic effects of metformin and (7) autophagy effects of
metformin.
1- Metformin induces growth inhibition
When Metformin is transported into the cells, it inhibits
mitochondrial complex I (NADH: ubiquinone oxidore-
ductase) which consider as the first and largest enzyme
of the respiratory chain and has a central role in cellular
energy production through the coupling of NADH: ubi-
quinone electron transfer to proton translocation [28].
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[29]. As a result, the AMP: ATP ratio in the cell is in-
creased, leading to energy stress and activation of AMPK
(AMP-activated protein kinase), a primary metabolic
sensor [30]. Hepatic AMPK activation can inhibit gluco-
neogenesis and activates glycolysis. In addition, AMPK
activation can increase glucose consumption in muscle.
Both of these consequences of metformin can diminish
hepatic glucose output leading to lower systemic glucose
and insulin levels, which could contribute to therapeutic
effect in type II diabetes and impair malignant growth
indirectly without requiring accumulation of metformin
in the tumor (indirect effect of metformin on tumors)
[31]. Furthermore, activation of AMPK leads to a cascade
of downstream events resulting in mammalian target of
rapamycin (mTOR pathway) down-regulation, which
eventually induces protein synthesis arrest and growth in-
hibition [32, 33]. There are two different multiprotein
complexes for mTOR, TORC1 and TORC2, which regu-
late protein synthesis necessary for cell growth, prolifera-
tion, angiogenesis, and other cellular endpoints [34].
Interestingly, mammalian target of rapamycin a member
of the phosphatidylinositol 3-kinase (PI3K) cell survival
pathway, plays an important role in the regulation of cell
growth and proliferation by monitoring nutrient availabil-
ity, cellular energy levels, oxygen levels and mitogenic
signals [35]. Aberrant activation of the PI3K pathway has
been widely implicated in many cancers, and increased ac-
tivity of this pathway is often associated with resistance to
cancer therapies [36].
Correlation of this pathway with bladder cancer
Several studies concluded that the AMPK pathway
might influence both bladder cancer development and
progression. A recent study by Liu et al. [37] reported
that rhodiola rosea extract and salidroside inhibit the
mTOR pathway and translational initiation via activation
of AMPKα in UMUC-3 bladder cancer cells. In addition,
PI3K and mTOR have prognostic/predictive value and
represent valuable therapeutic targets in bladder cancer
[38]. Metformin inhibits the proliferation of bladder
cancer cells in vitro and in vivo through activation of
AMPK and mTOR [19]. Moreover, metformin inhibits
the growth of bladder cancer cells via indirect activation
of AMPK [39, 40], which in turn suppresses the mTOR/
p70 S6 kinase-1 (S6K1) pathway in 253 J and RT4 blad-
der cancer cell lines.
2- Metformin regulates insulin and glucose levels
It is widely known that cancer cells express insulin as
well as Insulin-like Growth Factor (IGF), Insulin-like
Growth Factor Receptors (IGF-R) and that, besides its
metabolic effect, IGF-R promotes proliferation and metas-
tasis [41]. Cancer cells in particular have a constitutivelyhigh glucose uptake, independently of IGF-R activation
[42]. However, hyperinsulinemia may promote tumor
growth by various indirect mechanisms such as prolifera-
tion of epithelial tissue, increasing bioavailability of steroid
sex hormones and serum levels of IGF, as well as disrupt-
ing the homeostasis of adipokines, which are cytokines
selectively secreted by adipose tissue and thought to be
implicated in cancer pathogenesis [43]. In addition, IGF
activation promotes vascular smooth muscle cell prolifera-
tion and migration, promoting angiogenesis which could
contribute to tumor growth [44].
Metformin activates AMPK which results in inhib-
ition of gluconeogenesis in the liver, reducing insulin
and glucose levels and increasing glucose uptake in
skeletal muscle (a similar way as in metformin-treated
diabetic patients) [45]. Metformin is thought to reduce
ligand binding to insulin receptors; thus, metformin
can indirectly down-regulate the insulin signaling path-
way in tumours [46]. Moreover, metformin was shown
to directly inhibit insulin induced malignant as well as be-
nign cell growth in an AMPK/mTOR-dependent manner
[47]. Recently, metformin was shown to exert a more
direct effect on insulin signaling; by down-regulating a
downstream target of the insulin receptors called Insulin
Receptor Substrate-1 (IRS-1) [46]. The IRS-1 is a widely
expressed protein that, in the presence of insulin, becomes
phosphorylated by insulin receptors (or by IGF1-R) result-
ing in activation of downstream insulin-associated signal-
ing pathways like PI3K-AKT/Protein Kinase B(PKB) and
Ras-MAPK [48].
Correlation of this pathway with bladder cancer
Caloric intake appears to affect tumorigenesis through
IGF. Higher caloric intake has been associated with an
increased incidence of bladder cancer in American men
less than 65 years of age [49]. In addition, the decreased
caloric intake in mice slowed the growth of bladder
tumors and this effect was reversed by IGF-1 adminis-
tration [50]. Similarly, study found patients with ele-
vated plasma IGF-1 levels to be three times more likely
to develop bladder cancer [51]. Interestingly, study
demonstrated that cells of human bladder cancer trans-
fected with hsa-miR-96 inhibitor significantly reduced
the growth of bladder cancer cells through reduction of
mRNA and protein levels of IRS1 [52].
3- Metformin induces cell death
Metformin was shown to promote cell death across mul-
tiple cell lines through both caspase-dependent and
caspase-independent mechanisms [53]. It was shown that
metformin decreases the expression of anti-apoptotic pro-
teins B-cell lymphoma- 2 (BCL-2), B-cell lymphoma-
extra-large (Bcl-Xl) and Myeloid cell leukemia-1 (Mcl-1),
resulting to induction of the pro-apoptotic proteins,
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Death promoter (BAD) which lead to activation of cas-
pases and apoptosis in Ovarian Cancer (OC) [54]. Metfor-
min is also induced apoptosis by a caspase-independent
mechanism involving the activation of PARP which results
in nuclear translocation of AIF that leads to apoptosis
[55]. More importantly, AMPK/mTOR-mediated decrease
of suvivin in vivo which contributed in metformin-
induced apoptosis of gastric cancer cell [56].Correlation of this pathway with bladder cancer
A recent study concluded that nortriptyline has antitu-
mor on human and mouse bladder cancer cells through
induction of both intrinsic and extrinsic apoptosis. It in-
creases the expression of Fas, FasL, FADD, Bax, Bak,
and cleaved forms of caspase-3, caspase-8, caspase-9,
and Poly (ADP-ribose) Polymerase (PARP). It also de-
creases the expression of Bcl-2, Bcl-xL, BH3 interacting
domain death agonist, X-linked inhibitor of apoptosis
protein, and survivin [57]. Survivin inhibits apoptosis by
blocking activation of effector caspases in both extrinsic
and intrinsic pathways of apoptosis. Moreover, survivin
has also been indicated as a suitable target for develop-
ing specific therapy for local treatment of bladder can-
cer. Thus, survivin is a potentially significant protein
with a crucial role in the diagnosis, prognosis and treat-
ment of bladder cancer [58].4- Metformin potentiates the cytotoxicity of
chemotherapeutic drugs
Metformin was shown to potentiate the cytotoxic
effects of cisplatin in vitro [32] and in vivo studies; for
instance metformin and cisplatin synergistically re-
duced size, proliferation and mitotic count of OC tu-
mours in mice [59]. Metformin was shown also to
potentiate the cytotoxic effects of carboplatin using OC
cell lines and primary cultures from OC patients in ad-
vanced stages (III-IV) [60]. Moreover, in vitro studies
showed that metformin acts synergistically with pacli-
taxel and potentiates its growth inhibitory effects in
endometrial cancer [61]. Similarly, a study showed that
the combination of metformin with Phenethyl Isothio-
cyanate (PEITC) increases growth inhibition and cyto-
toxicity in OC cell lines in a synergistic manner [62].
Interestingly, several studies have shown the advantages
of combining metformin with standard cytotoxic drugs
like cisplatin [59], taxol [63] and doxorubicin [64] or
with molecular targeted agents such as gefitinib [65]. In
addition, metformin showed a synergic effect when
used in combination with 5-fluorouracil, in particular
affecting CD133+ colorectal cancer cells viability in
diabetic patients [66].5- Metformin’s association with oxidative stress, DNA
damage and DNA damage response (DDR)
There are several mechanisms that get activated after
DNA damage which occurred to avoid genomic in-
stability; they are known as DNA Damage Response
(DDR). One of the earliest DDRs is the activation of
γH2AX as a result of DSB. This response occurs within
minutes of the damage, thus making it a useful marker
of DNA damage. The description of events involved in
this activation in mammalian cells leading to γH2AX
[67]. The earliest responding proteins are those of the
Phosphatidylinositol 3-Kinase-Like family of Kinases
(PIKK) including Ataxia Telangiectasia-Mutated (ATM),
ATM- and Rad3-related (ATR) and the catalytic subunit
of DNA-dependent Protein Kinase (DNA-PKc) [68].
Metformin exerts a protective effect from DNA dam-
age as confirmed in several studies by reduction of
DNA damaged signaling, γH2AX expression, γH2AX
foci formation, ATM activation or Reactive Oxygen
Species (ROS) levels by inhibition of mitochondrial
complex I of the respiratory chain [68, 69]. Further-
more, inhibition of complex I compromises the elec-
tron flow in the electron transport chain, leading to
reduced production of ROS by complexes I and III
(mitochondrial ROS producers) [70].
Correlation of this pathway with bladder cancer
Mechanisms governing treatment-induced DNA damage
are both central to and predictive of bladder cancer cell
treatment sensitivity and exemplify a link between DNA
damage resistance and both treatment response and
tumour aggression [71]. On the other hand, study con-
ducted by Camargo et al., indicated that no relationship
was observed between the amount of DNA damage and
the level of hMLH1 (a gene involved in the mismatch re-
pair pathway) and RASSF1 (a tumor suppressor gene) in
bladder cancer cells treated with cisplatin and gemcita-
bine. They also confirmed other alternative pathways
might be involved in cisplatin and gemcitabine genotoxi-
city in bladder cancer cells [72].
6- Immune and hypothalamic effects of metformin
The concept of immune-modulating effects of metformin
was originally proposed in the 1950s by the Philippine
physician Garcia [73]. A recent study suggested that met-
formin can increase the number memory CD8 T cells in
wild type mice, and in consequence significantly improve
the efficacy of an experimental anticancer vaccine through
increased fatty acid oxidation [74]. In addition, study by
Ropelle et al., have shown that hypothalamic AMPK acti-
vation in response to metformin reverses cancer anorexia
in tumor bearing rats through inhibiting the production of
proinflammatory molecules and controlling neuropeptide
expression in the hypothalamus [75].
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A high fraction of adaptive immune markers CD3 (the
whole T cell population) and CD8 (T effector cells) in
bladder cancer indicated a poor prognosis, thereby
emphasising the important role that Tregs play in the
suppression of the anti-tumour immune response [76].
7- Autophagy effects of metformin
Autophagy is a self-degradative process that is important
for balancing sources of energy at critical times in devel-
opment and in response to nutrient stress. It also plays a
housekeeping role in removing misfolded or aggregated
proteins, clearing damaged organelles, such as mito-
chondria, endoplasmic reticulum and peroxisomes, as
well as eliminating intracellular pathogens. Thus, it is
generally thought of as a survival mechanism, although
its deregulation has been linked to non-apoptotic cell
death [77].
Metformin can enhance autophagy, as AMPK activa-
tion is known to upregulate autophagic activity through
direct phosphorylation of unc- 51-like kinase and Beclin
1, key molecules involved in the initiation of autophagy
[78]. The activation of AMPK by metformin proposes
the possibility that improvement in metabolic profiles by
metformin might be related to autophagy induction
through AMPK activation. In addition, metformin has
been shown to enhance disposal of accumulated autoph-
agic vacuoles in β-cells [79]. It has been reported also to
enhance autophagic activity in cardiac tissue by facilitat-
ing dissociation of the Bcl-2-Beclin 1 complex through
AMPK activation [80] and ameliorating ultra-structural
abnormalities associated with diabetes in an animal
model of diabetic cardiomyopathy [81]. Interestingly, a
recent study reported amelioration of hepatic steatosis
by metformin through autophagy activation via sirtuin 1
pathway rather than AMPK pathway [82]. The sirtuin 1
could influence autophagy directly via its deacetylation
of key components of the autophagy induction net-
work, such as the products of Autophagy genes (Atg) 5,
7, and 8 [83].
Correlation of this pathway with bladder cancer
A recent study showed that metformin suppresses
endometrial cancer cell growth through cell cycle arrest
and concomitant apoptosis and autophagy. These re-
sults indicated that the anti-proliferative effects and
apoptosis caused by metformin are partially or com-
pletely dependent on autophagy [84]. Similarly, several
studies have indicated that Troglitazone affects both
cell growth and differentiation progress and has an in-
hibitory effect on urinary cancer cells by activation of
autophagy concurrent with the activation of the AMPK
signaling pathway [85]. Moreover, further studies have
shown that gartanin treatment of bladder cancer celllines T24 and RT4 resulted in a marked induction of
autophagy and apoptosis [86].
Conclusion
There is lacking of ongoing or upcoming clinical studies
assessing the role of metformin in the therapy of bladder
cancer. Recently, metformin can inhibit the proliferation
of bladder cancer cells in vitro and in vivo. Moreover,
DM and obesity are considered as risk factors for blad-
der cancer. Metformin, a first-line oral anti-diabetic, has
been demonstrated to prevent cancer and reduce cancer
mortality among diabetic patients in several observa-
tional studies. Furthermore, metformin is commonly
used off-label for metabolic syndrome and treat weight
gain. Interestingly, metformin was shown to potentiate
the cytotoxic effects of numerous chemotherapeutic
drugs which common to be used in the treatment of
bladder cancer such as cisplatin, carboplatin, paclitaxel,
PEITC, doxorubicin, gefitinib and 5-fluorouracil. This is
the first review shed light on this direction to open the
door towards further researches and clinical studies on
the application of metformin as adjuvant therapy for
bladder cancer taken the advantages and proposed
mechanisms of anti-carcinogenic effects of metformin
which summarized in this review to confirm or not
novel usage of metformin through its ongoing journey
across cancer therapy.
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